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Simple Summary: Ischemic stroke is caused by the blockade of a blood vessel in the brain.
Consequently, the brain region supplied by the blocked vessel suffers brain damage and becomes
acidic. Here we provide a summary of the causes and consequences of acid accumulation in the
brain tissue. Ischemic stroke requires immediate medical attention to minimize the damage of brain
tissue, and to save function. It would be desirable for the medical treatment to target the site of injury
selectively, to enrich the site of ongoing injury with the protective agent, and to avoid undesirable
side effects at the same time. We propose that acid accumulation at the sight of brain tissue injury can
be used to delineate the region that would benefit most from medical treatment. Tiny drug carriers
known as nanoparticles may be loaded with drugs that protect the brain tissue. These nanoparticles
may be designed to release their drug cargo in response to an acidic environment. This would
ensure that the therapeutic agent is directed selectively to the site where it is needed. Ultimately,
this approach may offer a new way to treat stroke patients with the hope of more effective therapy,
and better stroke outcome.
Abstract: Ischemic stroke is a leading cause of death and disability worldwide. Yet, the effective
therapy of focal cerebral ischemia has been an unresolved challenge. We propose here that
ischemic tissue acidosis, a sensitive metabolic indicator of injury progression in cerebral ischemia,
can be harnessed for the targeted delivery of neuroprotective agents. Ischemic tissue acidosis,
which represents the accumulation of lactic acid in malperfused brain tissue is significantly exacerbated
by the recurrence of spreading depolarizations. Deepening acidosis itself activates specific ion channels
to cause neurotoxic cellular Ca2+ accumulation and cytotoxic edema. These processes are thought
to contribute to the loss of the ischemic penumbra. The unique metabolic status of the ischemic
penumbra has been exploited to identify the penumbra zone with imaging tools. Importantly,
acidosis in the ischemic penumbra may also be used to guide therapeutic intervention. Agents with
neuroprotective promise are suggested here to be delivered selectively to the ischemic penumbra
with pH-responsive smart nanosystems. The administered nanoparticels release their cargo in acidic
tissue environment, which reliably delineates sites at risk of injury. Therefore, tissue pH-targeted
drug delivery is expected to enrich sites of ongoing injury with the therapeutical agent, without the
risk of unfavorable off-target effects.
Keywords: acidosis; cerebral ischemia; penumbra; nanomedicine; neuroprotection; pH imaging;
smart nanosystem; spreading depolarization; tissue pH
Biology 2020, 9, 460; doi:10.3390/biology9120460 www.mdpi.com/journal/biology
Biology 2020, 9, 460 2 of 15
1. Introduction
Acute cerebral ischemia is a significant cause of irreversible brain injury. Global cerebral ischemia
is created by the complete cessation of blood supply to the brain associated most frequently with
cardiac arrest. Conversely, focal cerebral ischemia, which accounts for 80 % of all stroke cases, is caused
by the obstruction of a cerebral blood vessel by atherosclerosis or embolization [1]. Most often,
cerebral ischemia is incomplete. Adjacent to the core of the injury, residual blood flow persists,
the local cerebral blood flow (CBF) ranging between 15–25 mL/100 g/min or 20–40% relative to
baseline [2,3]. This narrow tissue band embracing the infarcted core has been known as the ischemic
penumbra [3]. In contrast with the necrotic core, the penumbra consists of electrophysiologically
inactive but viable and, most importantly, salvageable tissue [3–6], which places it in the center of
ischemic neuroprotective therapy.
It is important to realize that the penumbra evolves dynamically in space and time [7]. Over the
hours following the cerebrovascular occlusion, a significant volume of the peri-infarct penumbra may
be recruited to the necrotic infarction as spreading depolarizations (SDs) [8,9] propagate across tissue at
risk [7,10–13]. In fact, recurrent SDs, which are appreciated to arise at inner penumbra from minutes to
days after the primary impact, have been understood as the principal mechanism of lesion progression
in the acutely injured human brain [14,15]. In particular, SDs occur in hypoperfused nervous tissue
due to metabolic supply demand mismatch [16], and in turn, exacerbate the ischemia-related metabolic
burden [17]. The SD-linked metabolic challenge is faithfully reflected by tissue acidosis, the focus
of the present review [18,19]. Importantly, the metabolic crisis associated with SD [20] may prove
fatal to the penumbra tissue [21,22]. Over recent years, the opinion has been formulated that the
pattern of SD recurrence should be considered as a biomarker of metabolic failure in neurointensive
care [23], and SDs have been proposed as a therapeutic target in the management of acute brain injury,
including ischemic stroke [24].
Even though there is a pressing need for the successful treatment of focal cerebral ischemia,
clinical therapeutic options have been limited to the application of tissue plasminogen activator (tPA),
or mechanical thrombectomy [25]. Yet, a high proportion of ischemic stroke patients cannot benefit
from these interventions. Additional neuroprotective strategies are thus urgently required to alleviate
ischemic neuronal injury when recanalization is not an option, or as supportive, adjuvant treatment
after recanalization to mitigate reperfusion injury.
The development of drug delivery systems may be a key element to achieve successful
therapy [26–28]. The particular advantages of drug delivery systems in brain injury include that (i)
blood-brain barrier permeability for a specific drug is substantially increased, (ii) drug delivery can
be targeted selectively to sites at risk of injury, (iii) these systems carry the potential of gradual drug
release to elongate drug exposure, and (iv) local drug concentration may become high enough to exert
therapeutic effect, without the risk of drug accumulation in non-target tissues, which carries the risk of
undesirable side effects or off-target toxicity. “Smart” nanonsystems may meet all these requirements,
and provide an effective tool in the management of ischemic stroke [29,30].
This review is dedicated to provide an overview of tissue acidosis as it occurs in ischemic
stroke, particularly in the ischemic penumbra. First, a concise mechanistic insight into ischemic tissue
acidosis and acidotoxicity will be provided. Next, the utilization of tissue acidosis as a clinical tool to
outline the ischemic penumbra will be presented. Finally, tissue acidosis as a guide to therapeutic,
nanomedical intervention with the purpose to save the ischemic penumbra will be contemplated
(Figure 1).
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2. Mechanistic Insight into Ischemic Tissue Acidosis and Acidotoxicity 
2.1. Mechanisms to Cause Cerebral Ischemic Tissue Acidosis 
The shortage of metabolic substrates and oxygen, a condition that characterizes cerebral 
ischemia leads to metabolic acidosis. The limited availability of oxygen favors anaerobic glycolysis: 
pyruvate is reduced to lactate at the concomitant generation of a proton, which causes lactic acidosis 
[31]. In turn, tissue pH after cerebral ischemia onset decreases following an inversely linear 
relationship with tissue lactate concentration [31–34]. In addition, tissue pCO2 rises up to 3–4 fold, 
which may also contribute to tissue acidosis [35]. 
Even though astrocytes were initially thought to be a major source of acid production under 
cerebral ischemia [36,37], this interpretation was later contended and compartmentation of H+ was 
found to be negligible in the ischemic nervous tissue [34,38]. Intra- and extracellular acidosis with SD 
acquired at tissue level also displayed corresponding kinetics [19], indicating that acidosis in the 
intra-and extracellular space must be approximately matching in the metabolically challenged tissue. 
Indeed, intra-and extracellular pH in the ischemic nervous tissue probably equilibrates rapidly, 
because lactate newly produced in neurons and astrocytes is quickly released into the extracellular 
space as lactic acid via lactate/proton cotransport [39]. Metabolic acidosis may therefore not be 
restricted to specific cellular compartments. 
The spatial and temporal kinetics of metabolic acidosis changes dynamically with the 
progression of ischemia. As such, tissue pH in the ischemic core may become as low as pH 6.0, while 
tissue pH fluctuates around pH 6.5–6.9 in the peri-infarct penumbra, as estimated in the acute middle 
cerebral artery occlusion (MCAO) rodent model of focal ischemic stroke [40,41]. In case the tissue is 
reperfused, tissue pH in the ischemic penumbra may display an alkalotic shift (pH 7.63) in the first 
hour post-ischemia, which is followed by gradual acidosis over the following hours (down to pH 
6.58), coincident with infarct maturation [41,42]. In most studies dedicated to the exploration of 
cerebral ischemia-related tissue acidosis, the occurrence and contribution of SD has been overlooked 
[35,40,43]. It is important to recognize that the occurrence of SD transiently aggravates tissue acidosis, 
because SD propagating over the ischemic penumbra causes lactate load additional to that associated 
with hypoperfusion alone [18,44,45]. SD thus causes a decrease of tissue pH by around 0.3–0.5 pH 
units, taking off from mild or moderate acidosis [18,19] (Figure 2). For example, pH 6.9–7.1 was 
Figure 1. The stroke-associated metabolic acidosis of the nervous tissue, which is lethal to neurons
above a critical threshold (“Acidotoxicity”), may be harnessed for the accurate identification of the
ischemic penumbra (“Diagnostic tool”), or for focusing drug delivery selectively to the ischemic
penumbra (“Guide for therapy”) with smart nanosystems.
2. Mechanistic Insight into Ischemic Tissue Acidosis and Acidotoxicity
2.1. Mechanisms to Cause Cerebral Ischemic Tissue Acidosis
The shortage of metabolic substrates and oxygen, a condition that characterizes cerebral ischemia
leads to metabolic acidosis. The limited availability of oxygen favors anaerobic glycolysis: pyruvate is
reduced to lactate at the concomitant generation of a proton, which causes lactic acidosis [31]. In turn,
tiss e pH after cerebral ischemia onset decreases following an inversely linear relationship with tissue
lactate conce tration [31–34]. In addition, tissue pCO2 rises up to 3–4 fold, hich may also contribute
to tissue acidosis [35].
Even though astrocytes were initially thought to be a major source of acid production under
cerebral ischemia [36,37], this interpretation was later contended and compartmentation of H+ was
found to be negligible in the ischemic nervous tissue [34,38]. Intra- and extracellular acidosis with
SD acquired at tissue level also displayed corresponding kinetics [19], indicating that acidosis in
the intra-and extracellular space must be approximately matching in the metabolically challenged
tissue. Indeed, intra-and extracellular pH in the ische ic nervous tissue probably equilibrates rapidly,
because lactate newly prod ced in neurons and astrocytes is quickly released into the extracellular
space as lactic acid via lactate/proton cotransport [39]. Metabolic acidosis may therefore not be restricted
to specific cellular compartments.
The spatial and temporal kinetics of metabolic acidosis changes dynamically with the progression
of ischemia. As such, tissue pH in the ischemic core may become as low as pH 6.0, while tissue
pH fluctuates around pH 6.5–6.9 in the peri-infarct penumbra, as estimated in the acute middle
cerebral artery occlusion (MCAO) rodent model of focal ische ic stroke [40,41]. In case the tissue is
reperfused, tissue pH in the ischemic penumbra may display an alkalotic shift (pH 7.63) in the first
hour post-ischemia, which is followed by gradual acidosis over the following hours (down to pH 6.58),
coincident with infarct maturation [41,42]. In most studies dedicated to the exploration of cerebral
ischemia-related tissue acidosis, the occurrence and contribution of SD has been overlooked [35,40,43].
It is important to recognize that the occurrence of SD transiently aggravates tissue acidosis, because SD
propagating over the ischemic penumbra causes lactate load additional to that associated with
hypoperfusion alone [18,44,45]. SD thus causes a decrease of tissue pH by around 0.3–0.5 pH units,
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taking off from mild or moderate acidosis [18,19] (Figure 2). For example, pH 6.9–7.1 was measured in
the rat parietal cortex shortly after the bilateral occlusion of the common carotid arteries, but prior
to the spontaneous occurrence of SD [19]. The SD emerging within minutes after ischemia onset
aggravated tissue acidosis and decreased tissue pH down to 6.5 in average [19]. Further, the duration
of the SD-related acid burden corresponds to SD duration lasting for a few minutes under ischemic
penumbra conditions [46], which is increasingly longer in tissue zones undergoing more severe
metabolic crisis [14,17]. Moreover, the SD-related acid load is remarkably extended with aging in the
ischemic nervous tissue [46], which may contribute to the age-related acceleration of ischemic lesion
maturation [47]. Finally, recurrent SDs in close succession may pose a sustained lactic acid load [20,48].
This is of importance because the prolongation of acid exposure is understood to lower the threshold
of acidosis induced cell death [49]. Overall, SD may be perceived as a central mechanism of ischemic
tissue acidosis.
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Figure 2. Representative traces demonstrate the association of tissue acidosis (blue) with ischemia
onset (bilateral common carotid artery occlusion; (red) and spreading depolarization (SD); (black) in
the rat parietal cortex. Tissue pH was measured with a pH-sensitive microelectrode implanted in the
cortex, cerebral blood flow (CBF) was monitored with laser Doppler flowmetry, and the DC potential
was acquired with an intracortical glass capillary microelectrode.
2.2. Mechanistic Insight to Acidosis-Linked Neuronal Injury in Cerebral Ischemia
Excessive acidosis in the brain has long been considered to cause neuronal injury [32,49].
Furthermore, the detrimental impact of ischemic tissue acidosis on astrocyte function and survival has
also been extensively studied [50]. The traditional view holds that acute acidosis in the nervous tissue
leads to free radical generation, the failure of mitochondrial respiration, impaired protein synthesis,
compromised cellular Ca2+ buffering, the disruption of intracellular signal transduction pathways,
and the induction of DNA fragmentation [32,51–54]. In addition, tissue acidosis in cell culture has
been shown to activate cytokine receptors and inflammatory pathways implicated in delayed neuronal
injury subsequent to hypoxia [55].
The most recent mechanistic understanding of acidosis-linked neuronal death centers on the role
of specific pH sensitive ion channels and exchangers, and culminates in intracellular Ca2+ accumulation
or cytotoxic edema. As such, acid-sensing ion channel 1a (ASIC1a), a non-selective, proton-gated,
amiloride-sensitive cation channel is activated by the reduction of extracellular pH [56,57] (Figure 3).
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Neuronal ASIC1a was shown to give way to a non-voltage-gated influx of Ca2+ in response to
acidosis, which was suggested to contribute to the intracellular Ca2+ overload to initiate ischemic
cell death [58–60]. Next, NMDA receptor signaling was found to enhance the ASIC1a-mediated Ca2+
current under ischemia, because Ca2+/calmodulin-dependent protein kinase II phosphorylated ASIC1a
as a consequence of NMDA receptor activation [61]. Finally, ASIC1a was implicated in programmed
necrosis via the recruitment of the cell death regulator serine/threonine kinase receptor interaction
protein 1 (RIPK1) to ASIC1a in response to acidosis [62]. Importantly, ASIC1a inhibition proved to be
neuroprotective in the MCAO rodent model of focal cerebral ischemia [58], providing further support
to its implication in ischemic neuronal injury.
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Figure 3. Proposed cellular mechanisms of acidotoxicity in ischemic stroke include acidosis-related
intracellular Ca2+ overload and swelling of neurons (schematic gray-shaded cell). Decreasing extracellular
pH activates the acid-sensing ion channel 1a (ASIC1a) to allow direct Ca2+ influx to neurons. Low intra llular
pH facilitates H+/Na+ exchange, followed by the elimination of surplus intracellular Na+ via Na+/Ca2+
exchange. The ion movements lead to the ultimate intracellular accumulation of Ca2+. Low extracellular pH
also initiates Cl− influx through proton-activated Cl− (PAC) channels. The movement of Na+ (via NHE1)
and Cl− ( ia PAC channels) into the neurons attract water, increase the water content of cells and cause
cytotoxic edema. The mechanisms appear to be relevant for the SD-related tissue acidosis.
In addition to ASIC1a, a novel proton-activated Cl− (PAC) channel has recently been attributed an
acidotoxic role in c ebral ischemia [63] (Figure 3). The pathogenic potential of PAC channels lies in
that the influx of Cl− in response to acidosis causes cell swelling, and subsequent oncotic cell death [64].
The genetic knock-out of PAC channels provided partial neuroprotection in cultured neurons exposed
to acidosis, and in the MCAO focal cerebral ischemia model [63,65]. Of note, the persistent and
detrimental swelling of astrocytes exposed to lactacidosis was also linked to Cl− [66], in part because
the volume regulating Cl- efflux through normally operational volume-sensitive Cl- channels seemed
to be inhibited in the combined presence of lactate and low pH [67].
While ASIC1a and PAC channels are thus activated by extracellular acidosis, intracellular acidification,
as it occurs in cerebral ischemia, stimulates the operation of the Na+/H+ exchanger isoform 1 (NHE1),
which is abundant on neurons [57] (Figure 3). NHE1 function is augmented by the ischemia-related
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phosphorylation of the exchanger, through the extracellular signal-regulated kinase (ERK)/90-kDa
ribosomal S6 kinase (p90RSK) signaling pathway [68]. As a result, Na+ enters the cells in return for H+
extrusion, which attracts water to cause cell swelling [69]. Perhaps more importantly, the intracellular
accumulation of Na+ reverses the Na+/Ca2+ exchanger to expel surplus Na+, and increases concomitantly
the intracellular concentration of Ca2+ [70]. This then promotes cell death cascades linked to intracellular
Ca2+ accumulation [57]. As with ASIC1a, the genetic ablation or direct pharmacological inhibition of NHE1
decreased infarct volume, reduced apoptosis, or limited Zn2+ accumulation-related neurodegeneration
in experimental focal or global cerebral ischemia [70–72]. As a conclusion of these investigations,
the blockade of ASIC1a, PAC channels or NHE1 has been proposed as a therapeutic opportunity in
ischemic neuroprotection, with the aim to limit acidosis-linked neuronal injury [42,58,63,73].
3. Cerebral Tissue Acidosis in Theranostics and Nanomedicine
Brain imaging (computed tomography—CT, and magnetic resonance imaging—MRI) is a first
step in the diagnosis of ischemic stroke. Beyond the primary assessment of the nature (i.e., ischemic or
hemorrhagic), location, and volume of the injury of cerebrovascular origin, MRI and positron emission
tomography (PET) techniques have been central to identify the ischemic penumbra, prognosticate its
evolution, aid personalized therapeutic decision making, and confirm the fate of the penumbra tissue
after treatment [6,74]. The reliable differentiation of the ischemic penumbra from the infarction or
benign oligemic regions is, therefore, critical, and establishes the need to invent and refine applicable
imaging tools [5]. The most recent developments in this field suggest that tissue acidosis can be
used to distinguish penumbra tissue from the ischemic core with confidence, and the inclusion of
pH imaging among imaging modalities used in stroke diagnostics has been recommended to bring
informed decisions on patient care [6].
Obviously, the ischemic penumbra forms the central target of stroke therapy. Although recanalization
is clearly intended to reperfuse and ideally save the ischemic penumbra, the delivery of pharmacological
agents selectively to the penumbra zone is problematic, and remains a field for exploration. Next to narrow
therapeutic time-windows, obvious difficulties hamper drug delivery to the ischemic territory, including the
vascular occlusion blocking the direct vascular route of drug delivery, and the selective permeability
of the blood-brain barrier (BBB) if the BBB remains intact. Yet, the residual blood flow typical of the
ischemic penumbra may be sufficient in case the efficacy of drug delivery is amplified with specific drug
carrier and drug release systems that (i) can cross the intact BBB, (ii) respond to the ischemic environment,
and (iii) increase the local concentration of the therapeutic agent. Intriguingly, cancer therapy has already
identified low pH typical of the tumor environment to direct anticancer drug delivery selectively to a
tumor to enrich the tumor tissue with anticancer agents [75,76]. An analogous approach is thought to
open up new possibilities in ischemic stroke therapy [77,78], and may advance the management of
ischemic stroke in the future.
3.1. Tissue Acidosis to Identify Regions at Risk of Ischemic Damage
Fluorescent pH indicators have long been employed to visualize the spatial distribution of ischemic
tissue acidosis in experimental models of cerebral ischemia. The important first studies to present pH
images of coronal rodent brain slices used the pH sensitive fluorophores umbelliferone or neutral red,
with the limitation of providing no temporal resolution of pH variation because the brains were frozen
in situ at a chosen point of time for the subsequent ex vivo visualization of the pH signal [35,79,80]
(Figure 4). Later, live optical imaging of the neutral red-loaded cerebrocortical surface of anesthetized
rodents allowed high spatio-temporal resolution of the fluorescent pH signal [81], to follow the
evolution of ischemia-or SD-related acidosis [19,82,83] (Figure 4). Yet, inherent to the optical approach,
deeper brain regions escaped visualization, and the procedure of creating a craniotomy to serve
imaging is highly invasive.
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Figure 4. Experimental tissue pH imaging in models of cerebral ischemia and spreading depolarization.
(A), Umbilliferone fluorescence pH imaging 2 h after experimental middle cerebral artery occlusion
in the cat. Reprinted from Csiba et al., 1983 [80], with permission from Elsevier. (B–D), Neutral red
fluorescence imaging of spreading depolarization (SD) through a closed cranial window preparation over
the parietal cortex of an anesthetized rat. (B), The position of the closed cranial window. (C), An intrinsic
optical signal image of the exposed cortical surface at green light illumination. The schematic radial
hemi-circles indicate the wave of SD. (D), Transient tissue acidosis propagating with SD, depicted by the
increasing intensity of the Neutral red fluorescent signal (red) in background-subtracted, contrasted and
pseudo-colored images. Time with respect to SD initiation is shown in the lower right corner of
the images.
Much of the limitations of fluorescent indicator-based optical imaging appeared to be resolved
with the utilization of PET using tracers for pH measurement [84–86], and amide proton transfer
(APT) MRI, a type of chemical exchange saturation transfer imaging to visualize tissue acidosis [87,88].
Importantly, these imaging modalities focusing on acidosis have been applicable for stroke patients.
Tissue pH imaging with APT-MRI have been found to define the salvageable ischemic penumbra with
more confidence and better accuracy than the mismatch between perfusion- and diffusion-weighted
imaging, which have been recognized to delineate the outer and inner edge of the ischemic penumbra,
respectively [6,89]. Furthermore, APT-MRI was proposed as an imaging biomarker of clinical stroke
symptoms and treatment efficacy [90]. Finally, pH sensitive nanoparticles used as image contrast
enhancers to aid accurate distinction between diseased and normal tissue have been promising
diagnostic tools under development. For example, PET imaging that used pH sensitive 64Cu-labelled
polymers successfully delineated small tumors characterized by acidic pH in the mouse brain [91].
Also, Fe3O4 nanoparticles were demonstrated to be delivered to acidic ischemic brain tissue with pH
responsive polymeric micelles to enhance MR images in the rat MCAO model [92]. Taken together,
metabolic acidosis as it occurs in ischemic stroke emerges as a sensitive metabolic indicator to be
potentially used for the identification of the penumbra tissue at risk of being recruited to the irreversibly
damaged infarction, and to enable the design of personalized intervention in stroke therapy.
3.2. Tissue Acidosis to Guide Neuroprotective Intervention in Ischemic Stroke
The application of biocompatible and biodegradable, natural or synthetic macromolecular polymeric
nanocarriers offers substantial promise in therapeutics [93–95]. Among others, stimulus responsive
nanoparticles present the opportunity to initiate drug release by local (patho)physiological biochemical
stimuli (e.g., homeostatic, redox, enzymatic, tissue pH) [96–98], which are intrinsic and restricted to the
diseased tissue, and follow the progression of the disease condition. These bioresponsive nanomaterials
are also known as “smart” nanosystems [29]. A negative pH shift from the neutral 7.3–7.4 to below
7.0 units, for instance, can initiate conformational or solubility changes in various smart nanosystems,
including polysaccharide chitosan nanoparticles, to allow drug release [29,76,78]. In accordance, the acidic
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local tumor environment created by intensive or dysregulated glucose metabolism [99–101] has been
utilized as a specific trigger for drug release in the treatment of solid cancers [76,102,103].
The achievements of cancer nanomedicine have inspired the application of nanotechnology in
the therapy of ischemic stroke, especially because these diverse disease entities share some distinct
pathophysiological processes [29]. Along with the disintegration of microvascular ultrastructure,
intensified generation or failing clearance of reactive oxygen species, and cellular immune reactions [29],
tissue acidosis occurs in tumors [99–101], as well as in ischemic brain tissue. Building on our experience
gained in the field of metabolic tissue acidosis associated with SD in the ischemic cerebral cortex [18,71],
we designed and constructed pH-responsive chitosan nanoparticles [78]. After it had been confirmed
in suspension that the nanoparticles released nimodipine when pH fell below pH 7.0 [78], we tested
the efficacy of drug delivery with the nanoparticles in a preclinical model of cerebral ischemia [77]
(Figure 5). Our working hypothesis posited that drug carrier, pH-sensitive nanoparticles should release
their cargo in response to acidic tissue pH (<pH 7.0) typical of the ischemic penumbra or SD-affected
nervous tissue. We have selected nimodipine, an L-type voltage-gated Ca2+ channel antagonist as
the drug to be delivered, because the cerebral vasodilator, SD limiting and ischemic neuroprotective
actions of nimodipine have been widely acknowledged [104–108], and reproduced in our lab [109,110],
to be used as a reference for the nanoparticle study. In the experiments, the typical cerebral vasodilator
effect of nimodipine carried by the nanoparticles became apparent only once tissue acidosis with
ischemia onset (drop of pH from about 7.29 to 6.9–7.1) or SD (tissue pH down to 6.7) had occurred.
Further, nimodipine suppressed SD and augmented the related CBF response [77], as expected [110]
(Figure 5). On the basis of these results, the important principle was formulated that tissue acidosis,
as it occurs in cerebral ischemia and in association with SD, could be used as a trigger for drug delivery
by a smart, bioresponsive nanosystem.
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These results are enc uraging, and also raise a number of further considerations for the potential
biomedical application of the principle of acidosis guided drug targeting. We washed the nanoparticle
suspension directly to the exposed cortical surface in our pre-clinical model, which offers data relevant
for potential intracerebroventricular, intraparenchymal or intrathecal drug delivery [27]. Yet, all these
methods are significantly invasive and carry the risk of inflammation. Therefore other routes of
administration that a more realistic in routine clinical c re need to be tested. An obvious option
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must be evaluated, because particles larger than 12–30 nm may not cross the BBB [111]. Further,
the retention of nanoparticles in non-target tissues (e.g., cells of the reticuloendothelial system) could
decrease the amount of circulating nanoparticles before their penetration to the brain [112]. Finally,
potentially low tissue pH prevailing in peripheral organs or body fluids (e.g., in the respiratory
system or the gastrointestinal tract) would perceivably cause off-target drug release. Although the
size of the nimodipine-loaded nanoparticles in our study was small enough for BBB penetration (i.e.,
4–6 nm) [78], the BBB permeability of chitosan nanoparticles may be improved by functionalizing
chitosan with antibodies that recognize receptors specific to BBB endothelial cells (e.g., transferrin
receptors) [113,114]. This should initiate the receptor-mediated transcytosis of the nanospheres.
In addition, cerebral ischemia may derange the BBB and enhance non-selective transendothelial
vesicular transport, or loosen the tight junctions between adjacent endothelial cells [115]. This may
allow drug carriers to reach the nervous tissue along with the extravasation of blood plasma. Of note,
SD itself is capable of increasing endothelial transcytosis and paracellular diffusion at the BBB [116–118],
and was found to facilitate drug delivery to the brain tissue [117]. Finally, the intracarotid, rather than
intravenous route of infusion of drug-loaded nanocarriers should provide direct access to the brain [119],
which could substantially reduce off-target retention and drug release at the periphery.
The intranasal application of the nanoparticles may be an alternative route of drug administration.
Chitosan, in fact, displays very good adhesion to the nasal mucosa due to the positively charged
nanoparticle surfaces [120], and enhances absorption through the nasal mucosa by disrupting the
intercellular tight junctions of the epithelium [121,122]. However, the nasal mucosa is acidic (pH 5.5–6.5).
This condition counter-indicates the nasal administration of acid responsive nanoparticles targeting
the brain, unless the nanoparticles are applied in a pH neutralizing buffer medium, or are supplied
with a protective coating during their passage through the nasal mucosa, which the particles should
shed before reaching the brain.
In summary, ischemic tissue acidosis in the brain may be utilized to direct bioresponsive
nanocarriers to release their drug cargo in response to acidic tissue pH. This approach would ensure
that pharmacological agents are targeted selectively to tissue at risk of injury in ischemic stroke,
with minimizing off-target effects. In fact, ASIC1a, PAC channel or NHE1 blockers that counteract
acidotoxicity (see under Mechanistic insight to acidosis-linked neuronal injury in cerebral ischemia)
may be delivered driven by tissue acidosis itself.
4. Conclusions
In summary, a key mechanism of tissue acidosis as it occurs in focal cerebral ischemia is the
accumulation of lactic acid, which is largely achieved by SD. Tissue acidosis is a sensitive metabolic
indicator of injury progression in cerebral ischemia, which makes acidosis suitable for the identification
of the salvageable ischemic penumbra. Further, acidosis exacerbates ischemic injury in the nervous
tissue. The acidotoxic cellular Ca2+ accumulation and cytotoxic edema, which are mediated by ion
channels sensitive to an acidic shift in tissue pH (e.g., ASIC1a, PAC channels, NHE1), may be limited
with the use of selective ion channel blockers. These agents with neuroprotective promise are suggested
here to be delivered selectively to the ischemic penumbra with pH-responsive smart nanosystems.
Tissue pH-targeted drug delivery is expected to enrich sites of ongoing injury with the therapeutical
agent, without the risk of unfavorable off-target side effects.
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